// App-Quantinova.ai

e16104 : Risk of left ventricular systolic dysfunction with sunitinib therapy in patients with metastatic renal cell carcinoma: A prospective cohort study.

Researchers

Presenter

  • Vivek Narayan

Principal Investigators

  • Le Wang

  • Mary Putt

  • Stephen Michael Keefe

  • Naomi B. Haas

  • Daniel John Lenihan

  • Igor Puzanov

  • Anna Catino

  • James Fang

  • Steven M. Ewer

  • Karen Moncher

  • Chantal El Amm

  • Guilherme Oliveira

  • Hari Narayan

  • Bonnie Ky

Medical Centers

  • Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • University of Pennsylvania, Philadelphia, PA

  • Merck & Co., Inc., Kenilworth, NJ

  • Vanderbilt University Medical Center, Nashville, TN

  • University of Utah School of Medicine, Salt Lake City, UT

  • Univeristy of Wisconsin, Madison, WI

  • University of Wisconsin School of Medicine, Madison, WI

  • University Hospitals Case Medical Center, Cleveland, OH

  • Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Cleveland, OH

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Hospital of the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

  • Systolic dysfunction

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Sunitinib

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved